A phase III clinical trial is currently investigating the therapeutic efficacy of Bruton’s tyrosine kinase (BTK) inhibitors in MS; these molecules inhibit microglial activation and are thought to promote a switch in microglial phenotype from a pro-inflammatory to a pro-myelinating type [14]. Here, BTK is linked to myeloid sarcoma.